Screener
Theravance Biopharma TBPH Stock-Based Comp
Stock-Based Comp at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Theravance Biopharma’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 8:00 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-093773
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Depreciation and amortization | 748 | 822 |
| Amortization and accretion on investment securities, net | (1,539) | (749) |
| Future royalty payment contingency interest accretion | — | 1,306 |
| Share-based compensation | 10,494 | 9,420 |
| Loss on disposal of property and equipment | — | 35 |
| Amortization of right-of-use assets | 2,132 | 1,906 |
| Deferred income taxes | (3,217) | (12,543) |
| Other | 68 | (73) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's stock-based comp?
- Theravance Biopharma (TBPH) reported stock-based comp of $5.99M in Q2 2026.
- How has Theravance Biopharma's stock-based comp changed year-over-year?
- Theravance Biopharma's stock-based comp increased by 31.9% year-over-year, from $4.54M to $5.99M.
- What is the long-term trend for Theravance Biopharma's stock-based comp?
- Over 4 years (2021 to 2025), Theravance Biopharma's stock-based comp has grown at a -26.1% compound annual growth rate (CAGR), from $62.06M to $18.48M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Theravance Biopharma's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude